Details of HTA project
Last updated: 15 July 2008 - Next update due: 22 July 2008
Research type: |
Primary Research (e.g. trial) |
Project title: |
The place of minimal access surgery amongst people with gastro-oesophageal reflux disease (GORD) - a UK collaborative study |
 Outputs in journals arising from this project
| |
Project ref: |
97/10/03 |
Cost: |
£1,105,903 |
Chief Investigator : |
Professor Adrian Grant, Professor of Health Services Research, Health Services Research Unit, University of Aberdeen |
Project Email |
reflux@hsru.abdn.ac.uk |
Start Date: |
June 2000. |
Publication date: |
October 2008. This project is at the editorial review stage. Delays in the review process can cause the forecast publication date to be delayed. |
Plain English Summary |
Gastro-oesophageal reflux is a term used to describe the backflow of acid from the stomach into the oesophagus (swallowing tube). Gastro-oesophageal reflux occurs when the valve at the lower end of the oesophagus does not work properly. Almost everyone experiences gastro-oesophageal reflux at some time. The usual symptom being heartburn. However, for some people, reflux can become serious and persistent enough to be regarded as a disease, and this is what is known as Gastro-Oesophageal Reflux Disease (GORD). The two main forms of treatment routinely used in the National Health Service are medication and surgery. Aim At present, it is unknown whether medical (drugs in the form of tablets) or surgical treatment (a 'key-hole' operation known as a laparoscopic fundoplication) is best for treating persistent symptoms of GORD. The main aim of the REFLUX Trial is to find out which of these two treatments is better. |
Abstract: |
1. To evaluate the clinical effectiveness, cost-effectiveness, and safety of a policy of relatively early laparoscopic surgery compared with continued medical management amongst people with GORD judged suitable for both policies. 2. To explore factors which may influence the relative performance of the two policies, such as patient preference, surgeon experience, pre-enrolment symptoms and signs, the underlying pathology, the type of operative procedure used or choice of therapy, and the time since surgery. 3. To explore the impact that various policies for using laparoscopic surgery would have on the NHS and society in respect of the costs or savings that they would imply for (a) those providing surgical care (in secondary care settings), (b) those providing long-term medical management (usually in primary care settings), and © those with GORD. |
MeSH* index primary terms: |
GASTROESOPHAGEAL-REFLUX Q-surgery |
MeSH* index secondary terms: |
HUMAN; RANDOMIZED-CONTROLLED-TRIAL; CLINICAL-TRIAL; QUALITY-OF-LIFE; COST-BENEFIT-ANALYSIS |
NRR* number, if applicable: |
N0484078103 (*National Research Register) |
ISRCTN* number: | ISRCTN 15517081 (*International Standard Randomised Controlled Trial Number) URL of this project on the Controlled Trials Website: http://www.controlled-trials.com/ISRCTN15517081 |
Project Protocol: |
Project protocol not available |
URL of this page: |
http://www.hta.ac.uk/1134 |
Outputs from this project
|
|
News feeds